Gemrab D 30mg/20mg Capsule SR is a combination pharmaceutical formulation containing Domperidone 30mg and Rabeprazole 20mg, designed for the management of gastrointestinal disorders. Domperidone, a dopamine D2 receptor antagonist, facilitates gastric motility and accelerates gastric emptying, thereby alleviating symptoms such as nausea, vomiting, and bloating associated with delayed gastric emptying or gastroparesis. Rabeprazole, a proton pump inhibitor (PPI), suppresses gastric acid secretion by irreversibly inhibiting the H+/K+ ATPase enzyme system of the gastric parietal cells, providing effective relief from acid-related disorders including gastroesophageal reflux disease (GERD), peptic ulcers, and Zollinger-Ellison syndrome. The sustained-release (SR) formulation ensures prolonged therapeutic plasma concentrations, enhancing efficacy and improving patient compliance by reducing dosing frequency. Gemrab D is indicated for patients requiring both prokinetic and acid-suppressive therapy to manage symptoms of acid reflux accompanied by delayed gastric emptying. It should be used under medical supervision, with caution in patients with known hypersensitivity to either component, cardiac arrhythmias, or hepatic impairment. Common adverse effects may include dry mouth, headache, and gastrointestinal disturbances. Gemrab D 30mg/20mg Capsule SR offers a synergistic approach to managing complex upper gastrointestinal conditions by combining prokinetic and antisecretory actions in a single dosage form.